Global Intranasal Corticosteroids Market Snapshot

According to Future Market Insights research, during the projected period, the global intranasal corticosteroids market is expected to grow at a CAGR of 5.0%. The market value is projected to increase from US$ 6.8 Billion in 2023 to US$ 11.2 Billion by 2033. The intranasal corticosteroids market was valued at US$ 6.5 Billion at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 4.8% in 2023.

Market Outlook:

Data Points Market Insights
Market Value 2022 US$ 6.5 Billion
Market Value 2023 US$ 6.8 Billion
Market Value 2033 US$ 11.2 Billion
CAGR 2023 to 2033 5.0%
Market Share of Top 5 Countries 54.1%
Key Market Players Merck & co., GlaxoSmithKline, AstraZeneca, Sanofi, Perrigo Co., Teva Pharmaceutical Industries, Glenmark Pharmaceuticals, Mylan, Novartis, Pfizer, Pharmascience

Nasal steroid sprays are a type of medication that delivers corticosteroids directly into the nasal passages to alleviate symptoms associated with nasal allergies, including sneezing and a runny nose. These sprays offer effective relief from hay fever and other nasal allergies, often serving as a viable alternative to oral allergy medications. It usually takes a few days of consistent use for the sprays to take effect. To maintain ongoing relief, it is important to use them daily throughout the allergy season.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Sales Analysis of Intranasal Corticosteroids Market from 2017 to 2022 Vs Market Outlook for 2023 to 2033

The market value for intranasal corticosteroids expanded at a CAGR of close to 4.9% between 2017 and 2022. The intranasal corticosteroids market is around 32.4% of the overall US$ 20.2 Billion global allergy treatment market in 2022.

The global market for intranasal corticosteroids experienced growth over past few decades driven by the increased prevalence of condition like allergic rhinitis and Chronic Obstructive Pulmonary Disease (COPD). This increased prevalence has impacted infants, young children, and the elderly population suffering from these conditions. Most corticosteroids used are for treatment of seasonal allergic rhinitis caused due to aeroallergen.

Companies have been constantly working towards development of products to treat allergy related conditions which are effective yet cost-efficient.

  • In 2012, Nippon Shinyaku Co., Ltd. launched a dry powder type steroid nasal spray called 'Erizas Nasal Powder 200µg 28-metered spray' in Japan. This innovative product was specifically designed to effectively treat allergic rhinitis.
  • The product being referred to is the inaugural dry powder steroid nasal spray available in Japan for once-daily use.

This particular nasal spray has the capability to alleviate three common symptoms associated with allergic rhinitis, namely sneezing, nasal discharge, and nasal congestion.

As a result of these advantageous qualities, there has been a notable rise in the demand for intranasal corticosteroids.

What are the Key Opportunities for the Intranasal Corticosteroids Manufacturers?

Using a corticosteroid spray consistently on a daily basis is the most effective way to experience its benefits. To reduce symptoms during pollen season, it is recommended to start using the spray at the beginning of the season. It is worth mentioning that nasal corticosteroid sprays are generally safe for adults, and there are specific types that are also safe for children aged 2 and older. Pregnant women can also use corticosteroid sprays safely, but it is important for them to consult with their healthcare provider to choose the options with the best safety record during pregnancy. This ensures that a wider population can benefit from the use of intranasal corticosteroids worldwide.

Prominent companies are actively pursuing acquisitions and expanding their operations to strengthen their product offerings and reach a broader customer base.

  • In July 2019, Berry Global Group, Inc. acquired RPC Group Plc (RPC) at USD 6.5 billion. This revolutionary merger cements its position as one of the world's largest plastic packaging firms.

The above factors are likely to drive the global market in next few years.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Factors Restraining the Demand for the Intranasal Corticosteroids?

Although all intranasal corticosteroids (INCSs) used for treating allergic rhinitis (AR) are generally considered safe and effective, variations in potency, molecular structure, and physicochemical and pharmacokinetic properties can lead to differences in their clinical effectiveness and safety profiles. Some common side effects associated with intranasal corticosteroids include headache, nausea and vomiting, drowsiness, light-headedness, palpitations, loss of taste, wheezing, nosebleeds (epistaxis), nasal ulceration, irritation of the nose and throat (nasopharyngeal irritation), musculoskeletal pain, immunosuppression, and an increased risk of infections.

  • A significant number of patients did not adhere to the prescribed instructions for taking their INCS medication, indicating that the quality of administration can be deemed inadequate for numerous patients.

However, patients with low incomes, especially in developing countries, find it difficult to afford inhaled and intranasal corticosteroids. As a result, they often have no choice but to rely on less effective oral medications.

Country-wise Insights

Why is USA a Prominent Market for Intranasal Corticosteroids s in Asia Pacific region?

The USA leads the North America market contributing around US$ 1.9 Billion in 2022.

Prevalence of allergies in the United States is relatively high, with millions of individuals suffering from seasonal and perennial allergies each year. The accessibility and availability of intranasal corticosteroid medications in the USA market contribute to their increased usage. Moreover, healthcare professionals in the USA are well-informed about the benefits of intranasal corticosteroids and frequently prescribe them to patients who require allergy relief.

In the United States, there are currently nine branded Intranasal Corticosteroid products available. Among them, Nasacort Allergy 24HR (triamcinolone acetonide) and Flonase Allergy Relief (fluticasone propionate) are available over the counter. Drug manufacturers are actively working to maximize the therapeutic effects of corticosteroid therapy while minimizing potential systemic adverse effects and improving patient adherence.

Overall, these factors contribute to the higher usage of intranasal corticosteroids in the United States.

What Makes the China a Large Market for Intranasal Corticosteroid fixation?

In 2022, the China held a dominant share of in the East Asia market and contributed around US$ 466.0 Million.

  • The prevalence of allergic rhinitis (AR) is estimated to range from 10% to 40% globally, and in China, it was reported to be between 11.1% and 17.6% from 2005 to 2011, as per National Institute of Health study published in 2023.

The increasing urbanization and adoption of Westernized lifestyles in developing countries, along with rapid economic growth, have contributed to a rising trend of AR in recent decades. The prevalence of AR in China varies widely. Additionally, the impact of air pollution and climate change on respiratory disorders cannot be disregarded.

  • A genetic epidemiologic study conducted in Jiangsu Province, involving 23,825 families, found that the heritability of AR was 81.86% across three generations. Research published in Allergy, Asthma & Immunology Research 2019, has indicated that higher levels of air pollution during oak pollen season could potentially increase the occurrence of allergic airway disease in individuals who are sensitive to allergens. This is because the presence of air pollutants may contribute to the greater availability of airborne pollen allergens, thus exacerbating the allergic response.

What Makes India a Highly Lucrative Market for Intranasal Corticosteroids?

India holds nearly 6.7% market share in the global market in 2022. India is the lucrative market region in the South Asian market in revenue terms in 2022.

Indian subcontinent has witnessed a rise in allergic rhinitis and asthma cases over the past few decades.

  • The Lancet Global Health Journal-2022, estimated that globally, around 300 million people suffer from asthma, with 37.9 million of them residing in India.
  • As per National institute of Health, 2018, a study conducted in India revealed that the prevalence of allergic rhinitis was 11.3% among children aged 6-7 years and 24.4% among children aged 13-14 years.

India, on a global scale, faces one of the significant levels of air pollution, primarily caused by fossil fuels, vehicular emissions, and biomass. Additionally, the use of incense, mosquito coils, and dhoop sticks contributes significantly to indoor pollution. All these factors cumulatively is expected to boost the global market for intranasal corticosteroids market in India.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Which form of dosage is more prevalent in intranasal corticosteroid market?

The global market for intranasal sprays reached a substantial value of US$ 4.7 Billion in 2022.

Nasal sprays are liquid medications that are administered by spraying them into the nose. They are specifically designed to alleviate discomfort and congestion caused by allergies. Nasal sprays come in two types of containers: pressurized canisters and pump bottles. Some commonly known examples of nasal sprays include Naselin Nasal Spray, Astelin, Astepro, Nazal Spray, Vicks Ultra Fine Mist, Otrivin Spray, and Sinarest Spray.

Why Allergic Rhinitis is the Leading Intranasal Corticosteroids in drug type?

During year 2022, Allergic rhinitis accounts for around 58.1% of the global market share. Intranasal corticosteroid (INCS) therapy is considered the preferred treatment option for allergic rhinitis (AR) as it effectively inhibits the degranulation of mast cells. While these sprays are generally safe to use, they are not typically recommended as the first-line therapy for allergic rhinitis due to their lower effectiveness in relieving symptoms compared to antihistamines or intranasal corticosteroids. Additionally, their dosing schedule of three or four times daily can be inconvenient.

Which segment of Drug Corticosteroids is Aiding the Global Market to Propel?

Fluticasone Propionate accounts for 25.3% of the global market share in 2022.

Fluticasone Propionate helps reduce airway inflammation, thus improving breathing followed by reduced symptoms like coughing, shortness of breath and wheezing. It is also available as a nasal spray for the treatment of allergic rhinitis.

Fluticasone Propionate is considered an effective and commonly prescribed medication for respiratory conditions, and it is available in various brand names and forms. However, it should only be used under medical supervision and as prescribed by a healthcare professional.

Which Distribution Channel is Benefiting the Global Market?

Retail pharmacies captured a significant market share of around 31.7% in 2022. Retail pharmacies have established a strong presence with numerous conveniently located branches in various neighbourhoods and communities. This widespread accessibility ensures that customers can easily purchase nasal corticosteroids without the need to travel long distances or wait for delivery. Secondly, these pharmacies are staffed with well-trained pharmacists who are capable of providing valuable guidance and recommendations to customers regarding the use of nasal corticosteroids. This personalized advice instils confidence in customers and empowers them to make informed decisions about their healthcare.

Competitive Landscape

In the market for intranasal corticosteroids, key players are implementing various strategies to increase their sales and generate revenue.

  • Novartis International, obtained FDA approval in December 2020 for their supplemental Biologics License Age Group (sBLA) for Xolair® (omalizumab), which is used as an add-on maintenance treatment for nasal polyps in adult patients who have not responded well to nasal corticosteroids. Covis Pharma.

Bayer Healthcare LLC received FDA approval on June 17, 2021, for the nonprescription use of Astepro. This approval allows allergy sufferers to use the nasal sprays without the assistance of a healthcare provider when needed.

Similarly, recent developments related to the company’s manufacturing the Intranasal Corticosteroids have been tracked by the team at Future Market Insights, which are available in the full report.

Report Scope as Per Intranasal Corticosteroids Industry Analysis

Attribute Details
Forecast Period 2023 to 2033
Historical Data Available for 2017 to 2022
Market Analysis US$ Million for Value
Key Regions Covered North America, Latin America, Europe, South Asia, East Asia, Oceania, and MEA
Key Countries Covered USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, India, Thailand, China, Indonesia, Malaysia, Japan, South Korea, Australia, New Zealand, GCC countries, Türkiye, Northern Africa and South Africa.
Key Market Segments Covered Indication, Dosage Form, Drug, Distribution Channel, Region
Key Companies Profiled
  • Merck & co.
  • GlaxoSmithKline
  • AstraZeneca
  • Sanofi
  • Perrigo Co.
  • Teva Pharmaceutical Industries
  • Glenmark Pharmaceuticals
  • Mylan
  • Novartis
  • Pfizer
  • Pharmascience
Report Coverage Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Pricing Available upon Request

Key Market Segments Covered in the Intranasal Corticosteroids Industry Research

By Drug:

  • Fluticasone Propionate
  • Budesonide
  • Beclomethasone Dipropionate
  • Mometasone Furoate
  • Triamcinolone Acetonide
  • Ciclesonide
  • Flunisolide
  • Tixocortol

By Indication:

  • Allergic Rhinitis (AR)
    • Seasonal AR
    • Perennial AR
  • Non-Allergic Rhinitis (NAR)
    • Infectious NAR
    • Vasomotor NAR
    • Atrophic NAR

By Dosage Form:

  • Intranasal Drops
  • Intranasal Sprays

By Distribution Channel:

  • Hospitals Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa

Frequently Asked Questions

Which industry is the key consumer of Intranasal Corticosteroids Market?

The primary consumer for Intranasal Corticosteroids is the allergy and asthma industry.

What is the Intranasal Corticosteroids market outlook in the United States?

The United States is poised to stay attractive, projecting a US$ 1.5 billion market by 2033.

What is the current market valuation of the Intranasal Corticosteroids Market?

The market is estimated to secure a valuation of US$ 6.8 billion in 2023.

How big will the Intranasal Corticosteroids Market?

The market is estimated to reach US$ 11.2 billion by 2033.

Which end-use industry holds lucrative opportunities in the market?

The allergy and asthma sector holds high revenue potential.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply-Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Development/Innovation Trends

4. Value Added Insights

    4.1. Product Adoption / Usage Analysis

    4.2. Disease Epidemiology

    4.3. Pipeline Assessment

    4.4. Recent Product Approvals/Launches

    4.5. Regulatory Landscape

    4.6. Value Chain Analysis

    4.7. Porter’s Analysis

    4.8. PESTLE Analysis, By Region

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Global Healthcare Expenditure Outlook

        5.1.3. Global Life Expectancy Outlook

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Per-Capita spend on Intranasal Corticosteroids

        5.2.2. Increasing Prevalence of Allergic Rhinitis

        5.2.3. Percentage of Population suffering from Allergic Rhinitis opting for Intranasal Corticosteroids

        5.2.4. Percentage of Population suffering from Non-Allergic Rhinitis using Intranasal Corticosteroids

        5.2.5. Product Adoption/Usage Rate

        5.2.6. Growing Product Awareness and Demand in emerging markets

        5.2.7. Growing R&D by marketers

        5.2.8. New Product Launches

        5.2.9. Cost of Product

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033

    6.1. Historical Market Value Analysis, 2017 to 2022

    6.2. Current and Future Market Value Projections, 2023 to 2033

        6.2.1. Y-o-Y Growth Trend Analysis

        6.2.2. Absolute $ Opportunity Analysis

7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug

    7.1. Introduction/ Key Findings

    7.2. Historical Market Size (US$ Million) Analysis by Drug

    7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug, 2023 to 2033

        7.3.1. Fluticasone Propionate

        7.3.2. Budesonide

        7.3.3. Beclomethasone Dipropionate

        7.3.4. Mometasone Furoate

        7.3.5. Triamcinolone Acetonide

        7.3.6. Ciclesonide

        7.3.7. Flunisolide

        7.3.8. Tixocortol

    7.4. Market Attractiveness Analysis By Drug

8. Global  Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Million) Value Analysis By Indication, 2017 to 2022

    8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033

        8.3.1. Allergic Rhinitis (AR)

            8.3.1.1. Seasonal AR

            8.3.1.2. Perennial AR

        8.3.2. Non-Allergic Rhinitis (NAR)

            8.3.2.1. Infectious NAR

            8.3.2.2. Vasomotor NAR

            8.3.2.3. Atrophic NAR

    8.4. Market Attractiveness Analysis By Indication

9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Dosage Form

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Million) Analysis By Dosage Form, 2017 to 2022

    9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Dosage Form, 2023 to 2033

        9.3.1. Intranasal Drops

        9.3.2. Intranasal Sprays

    9.4. Market Attractiveness Analysis By Dosage Form

10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2017 to 2022

    10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        10.3.1. Hospitals

        10.3.2. Retail Pharmacies

        10.3.3. Drug Stores

        10.3.4. Online Pharmacies

    10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region

    11.1. Introduction

    11.2. Historical Market Size (US$ Million) Analysis by Region, 2017 to 2022

    11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033

        11.3.1. North America

        11.3.2. Latin America

        11.3.3. Europe

        11.3.4. East Asia

        11.3.5. South Asia

        11.3.6. Oceania

        11.3.7. Middle East and Africa

    11.4. Market Attractiveness Analysis By Region

12. North America s Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    12.1. Introduction

    12.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022

    12.3. Current and Future Market size (US$ Million) Analysis and Forecast, By Market Taxonomy, 2023 to 2033

        12.3.1. By Country

            12.3.1.1. USA

            12.3.1.2. Canada

        12.3.2. By Drug

        12.3.3. By Indication

        12.3.4. By Dosage Form

        12.3.5. Distribution Channel

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Drug

        12.4.3. By Indication

        12.4.4. By Dosage Form

        12.4.5. By Distribution Channel

    12.5. Market Trends

    12.6. Key Market Participants - Intensity Mapping

    12.7. Drivers and Restraints - Impact Analysis

    12.8. Country Level Analysis & Forecast

        12.8.1. USA Market Analysis

            12.8.1.1. Introduction

            12.8.1.2. Market Analysis and Forecast by Market Taxonomy

                12.8.1.2.1. By Drug

                12.8.1.2.2. By Indication

                12.8.1.2.3. By Dosage Form

                12.8.1.2.4. By Distribution Channel

        12.8.2. Canada Market Analysis

            12.8.2.1. Introduction

            12.8.2.2. Market Analysis and Forecast by Market Taxonomy

                12.8.2.2.1. By Drug

                12.8.2.2.2. By Indication

                12.8.2.2.3. By Dosage Form

                12.8.2.2.4. By Distribution Channel

13. Latin America s Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    13.1. Introduction

    13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022

    13.3. Current and Future Market size (US$ Million) Analysis and Forecast, By Market Taxonomy, 2023 to 2033

        13.3.1. By Country

            13.3.1.1. Brazil

            13.3.1.2. Mexico

            13.3.1.3. Argentina

            13.3.1.4. Rest of Latin America

        13.3.2. By Drug

        13.3.3. By Indication

        13.3.4. By Dosage Form

        13.3.5. By Distribution Channel

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Drug

        13.4.3. By Indication

        13.4.4. By Dosage Form

        13.4.5. By Distribution Channel

    13.5. Market Trends

    13.6. Key Market Participants - Intensity Mapping

    13.7. Drivers and Restraints - Impact Analysis

    13.8. Country Level Analysis & Forecast

        13.8.1. Brazil Market Analysis

            13.8.1.1. Introduction

            13.8.1.2. Market Analysis and Forecast by Market Taxonomy

                13.8.1.2.1. By Drug

                13.8.1.2.2. By Indication

                13.8.1.2.3. By Dosage Form

                13.8.1.2.4. By Distribution Channel

        13.8.2. Mexico Market Analysis

            13.8.2.1. Introduction

            13.8.2.2. Market Analysis and Forecast by Market Taxonomy

                13.8.2.2.1. By Drug

                13.8.2.2.2. By Indication

                13.8.2.2.3. By Dosage Form

                13.8.2.2.4. By Distribution Channel

        13.8.3. Argentina Market Analysis

            13.8.3.1. Introduction

            13.8.3.2. Market Analysis and Forecast by Market Taxonomy

                13.8.3.2.1. By Drug

                13.8.3.2.2. By Indication

                13.8.3.2.3. By Dosage Form

                13.8.3.2.4. By Distribution Channel

14. Europe s Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    14.1. Introduction

    14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022

    14.3. Current and Future Market size (US$ Million) Analysis and Forecast, By Market Taxonomy, 2023 to 2033

        14.3.1. By Country

            14.3.1.1. Germany

            14.3.1.2. Italy

            14.3.1.3. France

            14.3.1.4. U.K.

            14.3.1.5. Spain

            14.3.1.6. BENELUX

            14.3.1.7. Russia

            14.3.1.8. Rest of Europe

        14.3.2. By Drug

        14.3.3. By Indication

        14.3.4. By Dosage Form

        14.3.5. By Distribution Channel

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Drug

        14.4.3. By Indication

        14.4.4. By Dosage Form

        14.4.5. By Distribution Channel

    14.5. Market Trends

    14.6. Key Market Participants - Intensity Mapping

    14.7. Drivers and Restraints - Impact Analysis

    14.8. Country Level Analysis & Forecast

        14.8.1. Germany Market Analysis

            14.8.1.1. Introduction

            14.8.1.2. Market Analysis and Forecast by Market Taxonomy

                14.8.1.2.1. By Drug

                14.8.1.2.2. By Indication

                14.8.1.2.3. By Dosage Form

                14.8.1.2.4. By Distribution Channel

        14.8.2. Italy Market Analysis

            14.8.2.1. Introduction

            14.8.2.2. Market Analysis and Forecast by Market Taxonomy

                14.8.2.2.1. By Drug

                14.8.2.2.2. By Indication

                14.8.2.2.3. By Dosage Form

                14.8.2.2.4. By Distribution Channel

        14.8.3. France Market Analysis

            14.8.3.1. Introduction

            14.8.3.2. Market Analysis and Forecast by Market Taxonomy

                14.8.3.2.1. By Drug

                14.8.3.2.2. By Indication

                14.8.3.2.3. By Dosage Form

                14.8.3.2.4. By Distribution Channel

        14.8.4. UK Market Analysis

            14.8.4.1. Introduction

            14.8.4.2. Market Analysis and Forecast by Market Taxonomy

                14.8.4.2.1. By Drug

                14.8.4.2.2. By Indication

                14.8.4.2.3. By Dosage Form

                14.8.4.2.4. By Distribution Channel

        14.8.5. Spain Market Analysis

            14.8.5.1. Introduction

            14.8.5.2. Market Analysis and Forecast by Market Taxonomy

                14.8.5.2.1. By Drug

                14.8.5.2.2. By Indication

                14.8.5.2.3. By Dosage Form

                14.8.5.2.4. By Distribution Channel

        14.8.6. BENELUX Market Analysis

            14.8.6.1. Introduction

            14.8.6.2. Market Analysis and Forecast by Market Taxonomy

                14.8.6.2.1. By Drug

                14.8.6.2.2. By Indication

                14.8.6.2.3. By Dosage Form

                14.8.6.2.4. By Distribution Channel

        14.8.7. Russia Market Analysis

            14.8.7.1. Introduction

            14.8.7.2. Market Analysis and Forecast by Market Taxonomy

                14.8.7.2.1. By Drug

                14.8.7.2.2. By Indication

                14.8.7.2.3. By Dosage Form

                14.8.7.2.4. By Distribution Channel

15. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    15.1. Introduction

    15.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022

    15.3. Current and Future Market size (US$ Million) Analysis and Forecast, By Market Taxonomy, 2023 to 2033

        15.3.1. By Country

            15.3.1.1. India

            15.3.1.2. Thailand

            15.3.1.3. Indonesia

            15.3.1.4. Malaysia

            15.3.1.5. Rest of South Asia

        15.3.2. By Drug

        15.3.3. By Indication

        15.3.4. By Dosage Form

        15.3.5. By Distribution Channel

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Drug

        15.4.3. By Indication

        15.4.4. By Dosage Form

        15.4.5. By Distribution Channel

    15.5. Market Trends

    15.6. Key Market Participants - Intensity Mapping

    15.7. Drivers and Restraints - Impact Analysis

    15.8. Country Level Analysis & Forecast

        15.8.1. India Market Analysis

            15.8.1.1. Introduction

            15.8.1.2. Market Analysis and Forecast by Market Taxonomy

                15.8.1.2.1. By Drug

                15.8.1.2.2. By Indication

                15.8.1.2.3. By Dosage Form

                15.8.1.2.4. By Distribution Channel

        15.8.2. Thailand Market Analysis

            15.8.2.1. Introduction

            15.8.2.2. Market Analysis and Forecast by Market Taxonomy

                15.8.2.2.1. By Drug

                15.8.2.2.2. By Indication

                15.8.2.2.3. By Dosage Form

                15.8.2.2.4. By Distribution Channel

        15.8.3. Indonesia Market Analysis

            15.8.3.1. Introduction

            15.8.3.2. Market Analysis and Forecast by Market Taxonomy

                15.8.3.2.1. By Drug

                15.8.3.2.2. By Indication

                15.8.3.2.3. By Dosage Form

                15.8.3.2.4. By Distribution Channel

        15.8.4. Malaysia Market Analysis

            15.8.4.1. Introduction

            15.8.4.2. Market Analysis and Forecast by Market Taxonomy

                15.8.4.2.1. By Drug

                15.8.4.2.2. By Indication

                15.8.4.2.3. By Dosage Form

                15.8.4.2.4. By Distribution Channel

16. East Asia s Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    16.1. Introduction

    16.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022

    16.3. Current and Future Market size (US$ Million) Analysis and Forecast, By Market Taxonomy, 2023 to 2033

        16.3.1. By Country

            16.3.1.1. China

            16.3.1.2. Japan

            16.3.1.3. South Korea

        16.3.2. By Drug

        16.3.3. By Indication

        16.3.4. By Dosage Form

        16.3.5. By Distribution Channel

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Drug

        16.4.3. By Indication

        16.4.4. By Dosage Form

        16.4.5. By Distribution Channel

    16.5. Market Trends

    16.6. Key Market Participants - Intensity Mapping

    16.7. Drivers and Restraints - Impact Analysis

    16.8. Country Level Analysis & Forecast

        16.8.1. China Market Analysis

            16.8.1.1. Introduction

            16.8.1.2. Market Analysis and Forecast by Market Taxonomy

                16.8.1.2.1. By Drug

                16.8.1.2.2. By Indication

                16.8.1.2.3. By Dosage Form

                16.8.1.2.4. By Distribution Channel

        16.8.2. Japan Market Analysis

            16.8.2.1. Introduction

            16.8.2.2. Market Analysis and Forecast by Market Taxonomy

                16.8.2.2.1. By Drug

                16.8.2.2.2. By Indication

                16.8.2.2.3. By Dosage Form

                16.8.2.2.4. By Distribution Channel

        16.8.3. South Korea Market Analysis

            16.8.3.1. Introduction

            16.8.3.2. Market Analysis and Forecast by Market Taxonomy

                16.8.3.2.1. By Drug

                16.8.3.2.2. By Indication

                16.8.3.2.3. By Dosage Form

                16.8.3.2.4. By Distribution Channel

17. Oceania s Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    17.1. Introduction

    17.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022

    17.3. Current and Future Market size (US$ Million) Analysis and Forecast, By Market Taxonomy, 2023 to 2033

        17.3.1. By Country

            17.3.1.1. Australia

            17.3.1.2. New Zealand

        17.3.2. By Drug

        17.3.3. By Indication

        17.3.4. By Dosage Form

        17.3.5. By Distribution Channel

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Drug

        17.4.3. By Indication

        17.4.4. By Dosage Form

        17.4.5. By Distribution Channel

    17.5. Market Trends

    17.6. Key Market Participants - Intensity Mapping

    17.7. Drivers and Restraints - Impact Analysis

    17.8. Country Level Analysis & Forecast

        17.8.1. Australia Market Analysis

            17.8.1.1. Introduction

            17.8.1.2. Market Analysis and Forecast by Market Taxonomy

                17.8.1.2.1. By Drug

                17.8.1.2.2. By Indication

                17.8.1.2.3. By Dosage Form

                17.8.1.2.4. By Distribution Channel

        17.8.2. New Zealand Market Analysis

            17.8.2.1. Introduction

            17.8.2.2. Market Analysis and Forecast by Market Taxonomy

                17.8.2.2.1. By Drug

                17.8.2.2.2. By Indication

                17.8.2.2.3. By Dosage Form

    17.9. By Distribution Channel

18. Middle East and Africa s Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    18.1. Introduction

    18.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022

    18.3. Current and Future Market size (US$ Million) Analysis and Forecast, By Market Taxonomy, 2023 to 2033

        18.3.1. By Country

            18.3.1.1. GCC Countries

            18.3.1.2. Türkiye

            18.3.1.3. Northern Africa

            18.3.1.4. South Africa

            18.3.1.5. Rest of Middle East and Africa

        18.3.2. By Drug

        18.3.3. By Indication

        18.3.4. By Dosage Form

        18.3.5. By Distribution Channel

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Drug

        18.4.3. By Indication

        18.4.4. By Dosage Form

        18.4.5. By Distribution Channel

    18.5. Market Trends

    18.6. Key Market Participants - Intensity Mapping

    18.7. Drivers and Restraints - Impact Analysis

    18.8. Country Level Analysis & Forecast

        18.8.1. GCC Market Analysis

            18.8.1.1. Introduction

            18.8.1.2. Market Analysis and Forecast by Market Taxonomy

                18.8.1.2.1. By Drug

                18.8.1.2.2. By Indication

                18.8.1.2.3. By Dosage Form

                18.8.1.2.4. By Distribution Channel

        18.8.2. Türkiye Market Analysis

            18.8.2.1. Introduction

            18.8.2.2. Market Analysis and Forecast by Market Taxonomy

                18.8.2.2.1. By Drug

                18.8.2.2.2. By Indication

                18.8.2.2.3. By Dosage Form

                18.8.2.2.4. By Distribution Channel

        18.8.3. Northern Africa Market Analysis

            18.8.3.1. Introduction

            18.8.3.2. Market Analysis and Forecast by Market Taxonomy

                18.8.3.2.1. By Drug

                18.8.3.2.2. By Indication

                18.8.3.2.3. By Dosage Form

                18.8.3.2.4. By Distribution Channel

        18.8.4. South Africa Market Analysis

            18.8.4.1. Introduction

            18.8.4.2. Market Analysis and Forecast by Market Taxonomy

                18.8.4.2.1. By Drug

                18.8.4.2.2. By Indication

                18.8.4.2.3. By Dosage Form

                18.8.4.2.4. By Distribution Channel

19. Market Structure Analysis

    19.1. Market Analysis by Tier of Companies

    19.2. Market concentration

    19.3. Market Share Analysis of Top Players (%)

    19.4. Market Presence Analysis

        19.4.1. Regional Footprint of Players

        19.4.2. Method Footprint of Players

        19.4.3. Channel Footprint of Players

20. Competition Analysis

    20.1. Competition Dashboard

    20.2. Branding and Promotional Strategies, By Key Players

    20.3. Key Development Analysis

    20.4. Competition Deep Dive

        20.4.1. GlaxoSmithKline

            20.4.1.1. Overview

            20.4.1.2. Product Portfolio

            20.4.1.3. SWOT Analysis

            20.4.1.4. Key Development

            20.4.1.5. Sales Footprint

            20.4.1.6. Strategy Overview

                20.4.1.6.1. Marketing Strategies

                20.4.1.6.2. Product Strategies

                20.4.1.6.3. Channel Strategies

        20.4.2. AstraZeneca

            20.4.2.1. Overview

            20.4.2.2. Product Portfolio

            20.4.2.3. SWOT Analysis

            20.4.2.4. Key Development

            20.4.2.5. Sales Footprint

            20.4.2.6. Strategy Overview

                20.4.2.6.1. Marketing Strategies

                20.4.2.6.2. Product Strategies

                20.4.2.6.3. Channel Strategies

        20.4.3. Sanofi

            20.4.3.1. Overview

            20.4.3.2. Product Portfolio

            20.4.3.3. SWOT Analysis

            20.4.3.4. Key Development

            20.4.3.5. Sales Footprint

            20.4.3.6. Strategy Overview

                20.4.3.6.1. Marketing Strategies

                20.4.3.6.2. Product Strategies

                20.4.3.6.3. Channel Strategies

        20.4.4. Perrigo Co.

            20.4.4.1. Overview

            20.4.4.2. Product Portfolio

            20.4.4.3. SWOT Analysis

            20.4.4.4. Key Development

            20.4.4.5. Sales Footprint

            20.4.4.6. Strategy Overview

                20.4.4.6.1. Marketing Strategies

                20.4.4.6.2. Product Strategies

                20.4.4.6.3. Channel Strategies

        20.4.5. Teva Pharmaceutical Industries

            20.4.5.1. Overview

            20.4.5.2. Product Portfolio

            20.4.5.3. SWOT Analysis

            20.4.5.4. Key Development

            20.4.5.5. Sales Footprint

            20.4.5.6. Strategy Overview

                20.4.5.6.1. Marketing Strategies

                20.4.5.6.2. Product Strategies

                20.4.5.6.3. Channel Strategies

        20.4.6. Glenmark Pharmaceuticals

            20.4.6.1. Overview

            20.4.6.2. Product Portfolio

            20.4.6.3. SWOT Analysis

            20.4.6.4. Key Development

            20.4.6.5. Sales Footprint

            20.4.6.6. Strategy Overview

                20.4.6.6.1. Marketing Strategies

                20.4.6.6.2. Product Strategies

                20.4.6.6.3. Channel Strategies

        20.4.7. Mylan

            20.4.7.1. Overview

            20.4.7.2. Product Portfolio

            20.4.7.3. SWOT Analysis

            20.4.7.4. Key Development

            20.4.7.5. Sales Footprint

            20.4.7.6. Strategy Overview

                20.4.7.6.1. Marketing Strategies

                20.4.7.6.2. Product Strategies

                20.4.7.6.3. Channel Strategies

        20.4.8. Novartis

            20.4.8.1. Overview

            20.4.8.2. Product Portfolio

            20.4.8.3. SWOT Analysis

            20.4.8.4. Key Development

            20.4.8.5. Sales Footprint

            20.4.8.6. Strategy Overview

                20.4.8.6.1. Marketing Strategies

                20.4.8.6.2. Product Strategies

                20.4.8.6.3. Channel Strategies

        20.4.9. Pfizer

            20.4.9.1. Overview

            20.4.9.2. Product Portfolio

            20.4.9.3. SWOT Analysis

            20.4.9.4. Key Development

            20.4.9.5. Sales Footprint

            20.4.9.6. Strategy Overview

                20.4.9.6.1. Marketing Strategies

                20.4.9.6.2. Product Strategies

                20.4.9.6.3. Channel Strategies

        20.4.10. Pharmascience

            20.4.10.1. Overview

            20.4.10.2. Product Portfolio

            20.4.10.3. SWOT Analysis

            20.4.10.4. Key Development

            20.4.10.5. Sales Footprint

            20.4.10.6. Strategy Overview

                20.4.10.6.1. Marketing Strategies

                20.4.10.6.2. Product Strategies

                20.4.10.6.3. Channel Strategies

21. Assumptions and Acronyms Used

22. Research Methodology

Recommendations

Healthcare

Nasal Antihistamines Market

October 2021

REP-GB-13708

June 2023

315 pages

Healthcare

Nasal Allergy Treatment Market

April 2023

REP-GB-17114

342 pages

Healthcare

Nasal Sprays Market

April 2021

REP-GB-13112

January 2023

250 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Intranasal Corticosteroids Market